comprehensive -WSS

comprehensive

author：fashion 2025-09-06 04:37:32 - browse：514

Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a handful of biotech companies are trying to develop next-generation, longer-lasting therapies based on a very different approach: RNA interference.

This Nobel Prize-winning science works by degrading the biological blueprints that RNA use to make proteins — without the genetic instructions, the troublesome proteins are never made and the gene is essentially muted.

If the companies succeed, it would be a significant shift in the obesity treatment revolution, away from weekly drugs targeting hormones to medications that could be given much less frequently — twice a year or even less — and pinpoint genetic contributors to weight.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Google and Epic fight stronger regulation of AI in health care

WSS

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

Democratic lawmaker calls for 'well

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

A public scorecard can help hold safety

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Google and Epic fight stronger regulation of AI in health care

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Apple is now the first public company to be valued at $3 trillion

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

How one medical school became remarkably diverse

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

Activists slam private health insurers over coverage restrictions

Cosmetics set for new safety regulation. Why the industry is on board

At least 13 dead in Texas as scorching temps continue

FDA approves RSV monoclonal antibody for infants, toddlers

FDA approval of Sarepta Duchenne genetic therapy gives me hope

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

Wikipedia

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

At Orexo, a ‘turning point’ for everything but digital health

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

As digital health tech proliferates, a new institute aims to cut through hype

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

entertainment

focus

knowledge

entertainment